Nanobiotix Stock Rises 3.15%: +675% Over One Year for the Biotech
Nanobiotix stock has risen by 3.15% this Wednesday midday to 26.20 euros, after closing at 25.40 euros the previous day. This rebound occurs in a context of a significant recovery of the CAC 40, which is up by 1.38% during the session. Over one year, the value of the French biotech has shown an impressive performance of 675%.
Recovery After a Decline
Nanobiotix is regaining momentum after a week of decline, with the stock having dropped nearly 7% over the last seven days. This downward phase is part of a very favorable quarterly dynamic, with a gain of 32.86% over three months. The price is currently above its 50-day moving average, which is at 22.65 euros, indicating the maintenance of a medium-term upward trend. However, the stock is trading below its 20-day moving average (27.61 euros), a sign that the recent correction has temporarily weighed on the short-term dynamics. The RSI, an indicator measuring the speed of price movements, stands at 47, in a neutral zone, far from overbought or oversold thresholds. The next identifiable resistance threshold is at 33.50 euros, while the major support is at 20.10 euros, well below the current price. Volatility over one month remains high at 23.16%, reflecting the inherently speculative nature of a stock of this profile.
Broad Market Rebound
Nanobiotix's progress this Wednesday is part of a broader rebound in the Paris market. The CAC 40 is up 1.38% in the session, while the SBF 120 shows a similar advance. The healthcare sector is supporting this trend: Sanofi is up by 1.77% and UCB by 1.21%. This resurgence of dynamics in European markets comes in a context of geopolitical relaxation, after the pronounced volatility observed at the beginning of the week. The generalized rebound benefits growth stocks such as biotechnologies, which had been among the most affected in previous sessions. The beta of Nanobiotix, measured at 0.32, however indicates that the stock has historically shown limited sensitivity to overall market movements. Therefore, today's progress is significant for a stock whose evolution depends primarily on its own operational and clinical catalysts.
